Skip to main content

Table 1 Clinical features of the study population (pathological complete response, pCR)

From: Quantitative multiparametric MRI predicts response to neoadjuvant therapy in the community setting

Patient #

Age [years]

ER/PR/HER2

Therapeutic regimen

Pathological response

1

54

+/−/−

doxorubicin/cyclophosphamide → paclitaxel

Non-pCR

2

41

+/+/+

doxorubicin/cyclophosphamide → paclitaxel/Herceptin

pCR

3

74

−/−/−

doxorubicin/cyclophosphamide → paclitaxel

Non-pCR

4

25

−/−/−

doxorubicin/cyclophosphamide → paclitaxel

Non-pCR

5

26

−/−/+

doxorubicin/cyclophosphamide → paclitaxel /Herceptin

pCR

6

41

−/−/−

Carboplatin/paclitaxel → doxorubicin/cyclophosphamide

pCR

7

37

−/−/−

Carboplatin/paclitaxel → doxorubicin/cyclophosphamide

Non-pCR

8

41

+/−/−

doxorubicin/cyclophosphamide → paclitaxel

pCR

9

47

+/+/−

doxorubicin/cyclophosphamide → paclitaxel

pCR

10

54

+/+/−

doxorubicin/cyclophosphamide → paclitaxel

Non-pCR

11

59

−/−/−

Pembrolizumab (or placebo)/Carboplatin/paclitaxel

Non-pCR

12

63

+/+/−

doxorubicin/cyclophosphamide → paclitaxel

Non-pCR

13

27

+/+/−

doxorubicin/cyclophosphamide → paclitaxel

Non-pCR

14

32

+/+/+

Taxotere/Carboplatin/Herceptin/Pertuzumab

Non-pCR

15

52

−/−/−

Carboplatin/paclitaxel → doxorubicin/cyclophosphamide

Non-pCR

16

38

−/−/−

Carboplatin/paclitaxel → doxorubicin/cyclophosphamide

pCR

17

38

−/−/−

Pembrolizumab (or placebo)/Carboplatin/paclitaxel

pCR

18

62

−/−/−

doxorubicin/cyclophosphamide → paclitaxel

Non-pCR

19

38

+/+/+

Taxotere/Carboplatin/Herceptin/Pertuzumab

Non-pCR

20

42

+/+/−

doxorubicin/cyclophosphamide → paclitaxel

Non-pCR

21

53

+/+/−

doxorubicin/cyclophosphamide → paclitaxel

Non-pCR

22

58

−/−/−

Pembrolizumab (or placebo)/Carboplatin/paclitaxel

Non-pCR

23

48

+/+/−

doxorubicin/cyclophosphamide → paclitaxel

Non-pCR

24

50

+/+/+

Taxotere/Carboplatin/Herceptin/Pertuzumab

Non-pCR

25

64

+/+/−

doxorubicin/cyclophosphamide → paclitaxel

Non-pCR

26

40

+/−/+

Taxotere/Carboplatin/Herceptin/Pertuzumab

pCR

27

31

−/−/−

doxorubicin/cyclophosphamide → paclitaxel

Non-pCR

28

54

−/−/−

Talazoparib

Non-pCR